Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $77.00 price objective on the biotechnology company's stock. HC Wainwright's target price would suggest a potential upside of 450.28% from the company's previous close.

Separately, Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Stock Up 2.4 %

Shares of Capricor Therapeutics stock traded up $0.32 during trading on Tuesday, reaching $13.99. The company's stock had a trading volume of 2,873,292 shares, compared to its average volume of 1,006,827. The business has a 50 day moving average price of $14.41 and a 200-day moving average price of $13.87. The company has a market capitalization of $636.26 million, a P/E ratio of -13.23 and a beta of 4.08. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. Magnus Financial Group LLC purchased a new stake in Capricor Therapeutics during the 4th quarter worth approximately $276,000. State Street Corp increased its stake in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. JPMorgan Chase & Co. increased its position in Capricor Therapeutics by 419.5% in the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after buying an additional 45,381 shares during the period. Point72 Asset Management L.P. acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $3,806,000. Finally, Black Diamond Financial LLC bought a new position in Capricor Therapeutics during the 4th quarter valued at $3,833,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.